

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

## TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A SUBMISSION UNDER 35 U.S.C. 371

ATTTORNEY'S DOCKET NUMBER

Le A 36 437

U.S. APPLICATION NO. (If known, see 37 CFR 1.5)

Not Assumed 7 / 1

INTERNATIONAL APPLICATION NO. INTERNATIONAL FILING DATE PRIOR TO LA FE CAN 10/25/03 (Oct 25, 2003) PRIOR TO LA FE CAN 11/8/02 (Nov 8, 20

TITLE OF INVENTION SUBSTITUTED QUINAZOLINES AS ANTIVIRAL AGENTS, ESPECIALLY AGAINST CYTOMEGALOVIRUSES								
APPLICANT(S) FOR DO/EO/US WUNBERG, et al.								
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:								
1.	This is a FIRST submission of items concerning a submission under 35 U.S.C. 371.							
2.	This is a SECOND or SUBSEQUENT submission of items concerning a submission under 35 U.S.C. 371.							
3.	This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (21) indicated below.							
4.	The US has been elected (Article 31).							
5.	A copy of the International Application as filed (35 U.S.C. 371(c)(2))							
	a. X is attached hereto (required only if not communicated by the International Bureau).							
	b.  has been communicated by the International Bureau.							
	c. is not required, as the application was filed in the United States Receiving Office (RO/US).							
6.	An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)).							
	a. X is attached hereto.							
_	b. has been previously submitted under 35 U.S.C. 154(d)(4).							
7. <b>X</b>	Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))							
	a. are attached hereto (required only if not communicated by the International Bureau).							
	b. have been communicated by the International Bureau.							
	c. have not been made; however, the time limit for making such amendments has NOT expired.							
	d. X have not been made and will not be made.							
8.	An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).							
9.	An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).							
10.	An English language translation of the annexes of the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).							
iten	ns 11 to 20 below concern document(s) or information included:							
11.	An Information Disclosure Statement under 37 CFR 1.97 and 1.98.							
12.	An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.							
13.	A preliminary amendment.							
14.	An Application Data Sheet under 37 CFR 1.76.							
15.	A substitute specification.							
16. 🔲	A power of attorney and/or change of address letter.							
17.	A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 37 CFR 1.821- 1.825.							
18.	A second copy of the published International Application under 35 U.S.C. 154(d)(4).							
19.	A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4).							
20.	Other items or information: 1. Certificate of Mailing under 37 C.F.R. 1.10; and 2. Return Receipt Postcare							

Page 1 of 2 Date of Deposit: 5/6/05

Express Label No.: E0909255325US

## ORIGINAL 0.6 MAY 2005

PTO-1390 (Rev. 12-2004)
Approved for use through 3/31/2007. OMB 0651-0021
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

U.S. APPLICAT	ION NO. (if known, see :	37 CFP 1.5)	INTERNATIONAL APPLIC	CATION NO.	ATTORNEY'S DOC	KET NUMBER		
Not Assigne	n 15341	<b>38</b>	PCT/EP03/011880		Le A 36 437			
	nguees are submitted:							
🗶 a) Basic na	ational fee	\$ 300.00						
b) Examin	ation fee	\$ 200.00						
x c) Search f	ee	\$ 500.00						
	TOTAL OF ABOVE CA	LCULATION	S =	\$1000.00	\$ 1000.00			
listing or co		ed in an elec	in paper over 100 sheets (exclutoration). The fee is \$250					
Total Sheets	Extra sheets		r of each additional 50 or fraction of (round up to a whole number)					
67 - 100 =	/50 =			× \$250.00	\$ 0.00			
	30.00 for furnishing the odate (37 CFR 1.492(e)).	\$						
CLAIMS	NUMBER FI	LED	NUMBER EXTRA	RATE	\$			
Total claims	:	- 20 =	0	x \$50.00	\$			
Independent clai	ims	- 3 =	0	x \$200.00	\$			
MULTIPLE DEP	ENDENT CLAIM(S) (if a	oplicable)	0	+ \$360.00	\$			
			TOTAL OF ABOVE CAL	CULATIONS =	\$ 1000.00			
					\$			
		\$ 1000.00						
	of \$130.00 for furnishing to date (37 CFR 1.492(f)).	he English tr	anslation later than 30 months fr	om the earliest	\$	•		
		s 1000.00						
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property								
	TOTAL FEES ENCLOSED = \$ 1000.00							
		Amount to be refunded:	\$					
		Amount to be charged:	\$ 1000.00					
a. A chec	ck in the amount of \$		to cover the above for	age is anciosad				
a. A check in the amount of \$ to cover the above fees is enclosed.  b. Please charge my Deposit Account No. 13-3372 in the amount of \$ 1000.00 to cover the above fees.  A duplicate copy of this sheet is enclosed.								
c. X  The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit t Account No. 13-3372 A duplicate copy of this sheet is enclosed.								
d. Fees are to be charged to a credit card. WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.								
NOTE: Where a		t under 37 C	FR 1.495 has not been met, a p		(37 CFR 1.137(a) or (b))	must be filed		
_				,	. 01.	_		
SEND ALL CORRESPONDENCE TO: Customer No. 35969  Jeffrey M. Greenman  Juliu A. Shimir								
Bayer Phar	rmaceuticals Corp							
400 Morgai		Shimei						
vvest mave	n, CT 06516							
		ON NUMBER						
ĺ		ON NUMBER						



## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: WUNBERG, et al.

Serial No.: [to be assigned] National Stage Filing of PCT/EP03/011880

Filed: herewith

For: SUBSTITUTED QUINAZOLINES AS ANTIVIRAL AGENTS, ESPECIALLY AGAINST

**CYTOMEGALOVIRUSES** 

MAIL STOP PCT COMMISSIONER FOR PATENTS P.O. BOX 1450 ALEXANDRIA, VA 22313-1450

## **CERTIFICATE OF MAILING UNDER 37 CFR 1.10**

I hereby certify that the attached correspondence comprising: Transmittal Letter to the United States Designated/Elected Office (DO/EO/US) Concerning a Fifing under 35 U.S.C. 371 [IN DUPLICATE]; Application Data Sheet under 37 C.F.R. 1.76; Preliminary Amendment; Original oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)); X English Translation of the Application (35 U.S.C. 371(c)(2)); × Copy of the International Application as filed (35 U.S.C. 371(c)(2)); Information Disclosure Statement under 37 C.F.R. 1.97 and 1.98 consisting of Transmittal of Information Disclosure Statement under 37 C.F.R. 1.97(b), Information Disclosure Citation (Modified Form PTO-1449) and copies of references cited therein; X Return Receipt Post Card; Other:

is, on the date shown below, being deposited with the United States Postal Service, in an envelope as "Express Mail Post Office to Addressee" Mailing Label Number <u>EO909255325US</u> addressed to:

Mail Stop PCT
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

5/6/o5 Date

Signature of Person Certifying / Mariellen Chapdelaine